Strategic Investors Sanguina has secured strategic investments from Georgia-based partners including Emory BioFoundry Institute, Invest Georgia, and Georgia Tech Research Impact Fund. This implies strong local validation and potential introductions to healthcare systems, academic medical centers, and state-backed health initiatives for pilot programs or expanded deployments.

Health System Partnerships The company already partners with healthcare systems and insurers to generate biomarker-driven datasets. This opens opportunities to expand with regional health networks, integrated delivery organizations, and payer-provider collaborations seeking remote blood health monitoring solutions and early-detection datasets.

FDA-Cleared Home Solution AnemoCheck Home received FDA clearance, signaling regulatory readiness and consumer accessibility. This strengthens go-to-market credibility for direct-to-consumer channels, employer health programs, and telehealth partners looking for home-based blood health monitoring tech.

Clinical Validation Sanguina’s technology is supported by published clinical data and millions of proprietary data points. This can be leveraged to win contracts with clinical institutions, research organizations, and life sciences companies seeking robust biomarker analytics and real-world evidence capabilities.

RADx Recognition RADx Maternal Health Challenge grand prize recognitions (2024 and 2025) provide third-party credibility and narrative for funding, grant opportunities, and partnerships with maternal health programs and digital health initiatives focused on at-home monitoring and risk prediction.